The atherogenicity of Lp(a) may be mediated mechanistically through the inhibition of plasmin and TGF-beta production in the blood vessel wall, promoting smooth muscle cell proliferation.
No takes yet. Share an insight, caveat, or question.
Should not yet change Lp(a) management; leaves open whether targeting plasmin/TGF-beta pathways alters clinical outcomes.
Harpel et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: